DLDan‐Qing Li

Dan‐Qing Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Research Subjects


Dan‐Qing Li has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Gui‐Ge Wang

    Department of Thoracic Surgery Peking Union Medical College Hospital Beijing China

    1 shared publication
  • Jia‐Qi Zhang

    Department of Thoracic Surgery Peking Union Medical College Hospital Beijing China

    1 shared publication
  • Tian‐Ge Wang

    Chinese Academy of Medical Sciences Plastic Surgery Hospital Beijing China

    1 shared publication
  • Yan‐Qing Wang

    Department of Thoracic Surgery Peking Union Medical College Hospital Beijing China

    1 shared publication
  • Zhong‐Xing Bing

    Department of Thoracic Surgery Peking Union Medical College Hospital Beijing China

    1 shared publication

Latest Publications

  • Open Access

    Silencing of circ_0000517 suppresses proliferation, glycolysis, and glutamine decomposition of non‐small cell lung cancer by modulating miR‐330‐5p/YY1 signal pathway

    by Zhong‐Xing Bing, Jia‐Qi Zhang, Gui‐Ge Wang, Yan‐Qing Wang, Tian‐Ge Wang, Dan‐Qing Li

    In recent years, circular RNA (circRNA) has been found to be involved in a variety of cancer processes. More and more attention has been paid to the research of circRNA in lung cancer. This study aims to investigate whether circ_0000517 affected the physiology of non‐small cell lung cancer (NSCLC) and the underlying mechanism. The results demonstrated that circ_0000517 was highly expressed in lung cancer tissues and cells, and overexpression of circ_0000517 was negatively correlated with the prognosis of NSCLC patients. Silencing of circ_0000517 significantly inhibited the proliferation, glycolysis, and glutamine decomposition of NSCLC cells in vitro and repressed the growth of xenografted tumors in vivo. Moreover, knockdown of circ_0000517 attenuated the expression of PCNA, HK2, LDHA, ASCT2, and GLS1. Further study found that circ_0000517 targeted miR‐330‐5p and miR‐330‐5p targeted YY1. In addition, miR‐330‐5p inhibitor reversed inhibition of cancer cell proliferation, glycolysis, and glutamine decomposition induced by si‐circ_0000517. In conclusion, our study revealed that silencing of circ_0000517 improved the progression of NSCLC through regulating miR‐330‐5p/YY1 axis.